Our Pricing

Wegovy vs Mounjaro: Compare UK Weight Loss Injections

Published on: June 03, 2026

Choosing between treatments requires a thorough wegovy vs mounjaro uk comparison to understand which injectable best suits your weight loss goals. Both are MHRA-licensed GLP-1 receptor agonists proven in clinical trials, but they differ in mechanism, efficacy, dosing schedules, and side effect profiles. At Cured Pharmacy, our UK-registered clinical team helps you navigate these options with transparent pricing and expert guidance.

How Wegovy and Mounjaro Work Differently

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 to regulate appetite and blood sugar levels [1]. By activating GLP-1 receptors in the brain and pancreas, semaglutide slows gastric emptying, increases feelings of fullness, and reduces hunger signals between meals.

Mounjaro contains tirzepatide, the UK's first dual GIP/GLP-1 receptor agonist, activating both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 pathways simultaneously [2]. This dual mechanism produces enhanced metabolic effects compared to single-pathway treatments, with clinical trials demonstrating superior weight reduction outcomes.

The dual-action approach of tirzepatide affects insulin secretion, glucagon suppression, and energy expenditure through complementary pathways, which may explain why Mounjaro achieved greater average weight loss in head-to-head comparative studies [2][3].

Clinical Trial Results: Wegovy vs Mounjaro Weight Loss Efficacy

In the STEP 1 trial, adults using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, with 83.5% of participants losing at least 5% of their initial body weight [1]. Participants on the maximum 2.4mg weekly dose experienced consistent weight loss throughout the trial period, with improvements in cardiovascular risk markers.

The SURPASS-2 trial directly compared tirzepatide against semaglutide in adults with type 2 diabetes. Patients on the highest tirzepatide dose (15mg) achieved average weight loss of 11.2kg compared to 5.7kg with semaglutide 1mg over 40 weeks [3]. Subsequent obesity-focused trials showed even greater results, with SURMOUNT-1 demonstrating average weight reductions up to 22.5% with tirzepatide 15mg over 72 weeks [2].

Both medications show dose-dependent efficacy, meaning higher prescribed doses generally correlate with greater weight loss, subject to individual tolerability and prescriber assessment [1][2]. Your UK prescriber will determine the appropriate starting dose and titration schedule based on your medical history and treatment response.

Real-World Weight Loss Expectations

Clinical trial results represent controlled conditions with dietary counselling and regular monitoring. Real-world outcomes vary based on adherence, lifestyle modifications, baseline metabolic health, and individual response to treatment. Most patients begin seeing measurable weight loss within 4-8 weeks of starting either medication, with continued gradual reduction over subsequent months when combined with reduced-calorie diet and increased physical activity.

Dosing Schedules and Administration

Both Wegovy and Mounjaro are administered as once-weekly subcutaneous injections using pre-filled pens, typically into the abdomen, thigh, or upper arm. The injection site should be rotated each week to minimise skin reactions.

Wegovy follows a fixed dose escalation schedule starting at 0.25mg weekly, increasing every four weeks through 0.5mg, 1mg, and 1.7mg, reaching the maintenance dose of 2.4mg by week 17 [4]. This gradual titration helps minimise gastrointestinal side effects as your body adjusts to the medication.

Mounjaro starts at 2.5mg weekly with dose increases every four weeks as tolerated, progressing through 5mg, 7.5mg, 10mg, 12.5mg, and up to a maximum of 15mg weekly [5]. The slower titration and wider dose range allow for more personalised treatment optimisation based on individual response and tolerability.

What Happens If You Miss a Dose

For both medications, if you miss a dose and fewer than five days have passed since your scheduled injection day, take it as soon as you remember. If more than five days have passed, skip the missed dose and resume your normal weekly schedule. Never take two doses within three days of each other, as this increases the risk of gastrointestinal side effects.

Side Effects: What to Expect with Each Treatment

The most common side effects for both Wegovy and Mounjaro are gastrointestinal, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][2]. These effects typically occur during dose escalation phases and often diminish as treatment continues, though some patients experience persistent symptoms.

In clinical trials, nausea occurred in approximately 44% of Wegovy users and 34-43% of Mounjaro users depending on dose, with most cases rated as mild to moderate [1][2]. Eating smaller, more frequent meals and avoiding high-fat foods may help manage these symptoms.

Both medications carry similar warnings regarding thyroid C-cell tumours observed in rodent studies, pancreatitis risk, gallbladder problems, and hypoglycaemia when used with insulin or sulfonylureas [4][5]. Neither should be used if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Some patients report injection site reactions, fatigue, or changes in taste. Serious allergic reactions are rare but require immediate medical attention if you experience difficulty breathing, severe rash, or facial swelling.

Cost Comparison and UK Availability

At Cured Pharmacy, Wegovy starts from £135.00 per pen, representing competitive UK pricing with transparent upfront costs shown before your clinical consultation. The final price depends on your prescribed dose and treatment duration, determined by your UK prescriber following assessment.

Pricing structures across UK pharmacies vary based on dose strength, supply duration, and whether you're purchasing maintenance doses or following the initial titration schedule. Cured Pharmacy guarantees the lowest prices in the UK with no hidden consultation fees or prescription charges.

Both medications are available through private prescription only in the UK, as NHS availability remains limited to specialist weight management services in most areas. All purchases require completion of a free online clinical assessment by a UK-registered prescriber, typically completed in under three minutes.

Insurance and NHS Coverage

NHS prescription of GLP-1 medications for weight loss follows strict NICE guidelines, typically reserved for patients with BMI ≥35 with weight-related complications or BMI ≥30 with specific conditions, accessed through specialist services. Private prescriptions offer faster access without lengthy waiting lists, with treatment costs not typically covered by standard health insurance policies in the UK.

Which Treatment Is Right for You: Wegovy vs Mounjaro UK

Your choice between Wegovy and Mounjaro depends on multiple factors including your weight loss goals, medical history, tolerance for side effects, dosing preferences, and budget considerations. Patients seeking maximum weight loss outcomes may prefer Mounjaro based on superior trial results, whilst those prioritising established long-term safety data and lower starting costs may choose Wegovy.

Certain medical conditions influence suitability for each medication. Your UK prescriber will review contraindications including previous pancreatitis, severe gastrointestinal disease, diabetic retinopathy complications, and kidney function. Both medications require caution in patients with history of eating disorders or depression.

The online consultation at Cured Pharmacy includes a comprehensive medical questionnaire reviewed by our UK-registered clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). Based on your responses, our prescribers recommend the most appropriate treatment or suggest alternative options if GLP-1 medications aren't suitable.

Many patients achieve successful weight loss with either medication when combined with sustainable lifestyle changes. The 'best' choice is the one you can adhere to consistently, tolerate well, and afford long-term, as weight management typically requires ongoing treatment to maintain results.

Starting Your Treatment Journey

Beginning treatment involves completing your free online assessment, receiving prescriber approval, and having your medication dispensed from our UK-registered pharmacy with discreet next-day delivery. Our clinical team remains available throughout your treatment for dose adjustments, side effect management, and ongoing support as you progress towards your weight loss goals.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency (MHRA). Retrieved from https://www.gov.uk/ [accessed 13 August 2026]
5. Eli Lilly. (2023). Mounjaro (tirzepatide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency (MHRA). Retrieved from https://www.gov.uk/ [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, lifestyle modifications, and individual metabolic factors.